Jun 14, 2022 / 08:20PM GMT
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research Analyst
Hi, everyone. Welcome to the afternoon sessions at our conference. My name is Nathan Rich, and I cover the U.S. generic space at Goldman. And I'm going back to the -- my colleague. We're very pleased to welcome Viatris for our next session. We're joined by the company's President, Rajiv Malik, CFO; Sanjeev Narula and Bill Szablewski, who runs Capital Markets and Investor Relations. Good to see all of you. I'm sorry that it had to be virtually. I'm sorry, Michael wasn't able since to make it as well. There's always next year, right?
Questions and Answers:
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research AnalystSo why don't we jump into the Q&A, if that's okay. And I wanted to start maybe, Rajiv, with you, a high level one on the strategy. At the Analyst Day earlier this year, you announced the divestiture of your biosimilar business results some other asset sales that you plan to do kind of reprioritize capital deployment towards share
Trustpilot
